Pemziviptadil (PB1046)

DRUG2 trials

Sponsors

PhaseBio Pharmaceuticals Inc.

Conditions

Acute Respiratory Distress SyndromeCOVID 19Cardiac ComplicationCardiac DysfunctionCardiac EventCardiac FailureCardiac InfarctCoronavirus

Phase 2

Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH

TerminatedNCT03556020

PhaseBio Pharmaceuticals Inc.Pulmonary Arterial Hypertension

Start: 2018-07-15End: 2022-01-07Updated: 2022-08-23

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

TerminatedNCT04433546

PhaseBio Pharmaceuticals Inc.Acute Respiratory Distress Syndrome, Cardiac Complication, Cardiac Dysfunction +15

Start: 2020-07-15End: 2020-12-02Updated: 2020-12-11